Investor

Overview Share information Financial calendar Reports & presentations Governance

Investor relations

We are committed to providing all shareholders and potential investors with consistent, transparent, and relevant financial information. This section offers key insights into Lifecare.

NOK –

Last updated 1970-01-01 00:00:00

Change +0.00

Volume 0,000

High 0.00 NOK

Low 0.00 NOK

Join our journey

Lifecare is a Norwegian med-tech company developing sensors to measure and monitor biomarkers. We focus on diabetes, aiming to bring the next generation of continuous glucose monitoring (GCM) systems to improve diabetes management for humans and pets.

Investment case

Company presentation

Learn more about Lifecare and how we intend to create value for our stakeholders.

Lifecare as an investment

The GCM market (for humans) surpassed $10 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8-13% until 2030. Lifecare’s technology is proprietary and patented, and has undergone extensive laboratory testing, as well as controlled animal trials. The company is in the clinical trial phase and successfully completed the first human study of its glucose sensor in 2023. We expect to launch our GCM sensor in the pet market in 2025 and aim for CE approval for the human market in 2026.

Stock exchange notices

IR contacts

Joachim Holter

Chief Executive Officer

+47 400 59 040 joacim.holter@lifecare.no

Renete Kaarvik

Chief Financial Officer

+47 94838242 renete.kaarvik@lifecare.no